Laura Chico
Stock Analyst at Wedbush
(3.00)
# 1,401
Out of 4,931 analysts
212
Total ratings
36.77%
Success rate
1.38%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $1.98 | +152.53% | 6 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $5.20 | +169.23% | 14 | Aug 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $137 → $141 | $128.43 | +9.79% | 10 | Jul 31, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $35 → $34 | $28.05 | +21.21% | 13 | Jul 14, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $17 | $14.25 | +19.30% | 1 | Jul 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $16 → $18 | $8.60 | +109.30% | 1 | Jun 30, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $17 → $15 | $3.77 | +297.88% | 2 | Jun 24, 2025 | |
| LEN Lennar | Reiterates: Neutral | $130 | $119.35 | +8.92% | 1 | Jun 18, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $121 | $129.34 | -6.45% | 18 | Jun 12, 2025 | |
| PHVS Pharvaris | Reiterates: Outperform | $27 | $21.28 | +26.88% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $17.24 | +74.01% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $6.51 | +161.14% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $7.92 | +114.78% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $3.10 | +29.03% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $14.35 | +109.06% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $19.25 | +35.06% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $48.60 | -42.39% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $13.52 | +218.17% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $21.94 | +95.99% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.51 | +488.00% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $20.39 | +76.56% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $6.93 | +304.04% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $23.73 | +22.21% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.37 | +775.91% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $34.27 | +42.98% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.40 | +105.88% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $17.20 | +144.19% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $13.17 | +29.08% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.53 | +1,984.52% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.35 | +14.94% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $60.67 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.79 | +79.21% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.06 | +886.06% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.11 | +7,803.40% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $61.99 | +351.69% | 1 | Apr 21, 2017 |
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.98
Upside: +152.53%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.20
Upside: +169.23%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $128.43
Upside: +9.79%
Ultragenyx Pharmaceutical
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $28.05
Upside: +21.21%
Maze Therapeutics
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $14.25
Upside: +19.30%
BioCryst Pharmaceuticals
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.60
Upside: +109.30%
Larimar Therapeutics
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.77
Upside: +297.88%
Lennar
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $119.35
Upside: +8.92%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $129.34
Upside: -6.45%
Pharvaris
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $21.28
Upside: +26.88%
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $17.24
Upside: +74.01%
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $6.51
Upside: +161.14%
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $7.92
Upside: +114.78%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $3.10
Upside: +29.03%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $14.35
Upside: +109.06%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $19.25
Upside: +35.06%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $48.60
Upside: -42.39%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $13.52
Upside: +218.17%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $21.94
Upside: +95.99%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.51
Upside: +488.00%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $20.39
Upside: +76.56%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $6.93
Upside: +304.04%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $23.73
Upside: +22.21%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.37
Upside: +775.91%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $34.27
Upside: +42.98%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.40
Upside: +105.88%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $17.20
Upside: +144.19%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $13.17
Upside: +29.08%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.53
Upside: +1,984.52%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.35
Upside: +14.94%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $60.67
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.79
Upside: +79.21%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.06
Upside: +886.06%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.11
Upside: +7,803.40%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $61.99
Upside: +351.69%